Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Progression of RAS-mutant leukemia during RAF inhibitor treatment.

The New England journal of medicine - 13 Dec 2012

Callahan Margaret K, Rampal Raajit, Harding James J, Klimek Virginia M, Chung Young Rock, Merghoub Taha, Wolchok Jedd D, Solit David B, Rosen Neal, Abdel-Wahab Omar, Levine Ross L, Chapman Paul B

Abstract excerpt

Vemurafenib, a selective RAF inhibitor, extends survival among patients with BRAF V600E-mutant melanoma. Vemurafenib inhibits ERK signaling in BRAF V600E-mutant cells but activates ERK signaling in BRAF wild-type cells. This paradoxical activation of ERK signaling is the mechanistic basis for the development of RAS-mutant squamous-cell skin cancers in patients treated with RAF inhibitors. We report the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, ras
Share to Indoles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia, Myelomonocytic, Chronic

Share to Leukocyte Count

Share to Melanoma

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 23134356
DOI: 10.1056/NEJMoa1208958
PMCID: PMC3627494

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Progression of RAS-mutant leukemia during RAF inhibitor treatment.PMID 23134356Read ↗

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.Semantic proximity Read ↗

Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells.Semantic proximity Read ↗

BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Semantic proximity Read ↗

Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.Semantic proximity Read ↗

Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma CancersSemantic proximity Read ↗

Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.Semantic proximity Read ↗

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.Semantic proximity Read ↗

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with VemurafenibSemantic proximity Read ↗

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.Semantic proximity Read ↗

Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR ExpressionSemantic proximity Read ↗

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors.Semantic proximity Read ↗

RAF inhibitors that evade paradoxical MAPK pathway activation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.